Warning letter
HealthPartners Neuroscience Center Research and Innovation: warning letter of May 19, 2026
FDA warning letter 725333 · Center for Drug Evaluation and Research (CDER)
Key facts
| Reference number | 725333 |
|---|---|
| Company | HealthPartners Neuroscience Center Research and Innovation |
| Subject | Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies |
| Issue date | May 19, 2026 |
| Posted date | Jun 2, 2026 |
| Issuing office | Center for Drug Evaluation and Research (CDER) |
| Product type | Drugs |
| CFR sections cited | 58.31(e), 58.113(a)(1), 58.81(a), 58.61, 58.35(b)(6), 58, 58.31(d) |
| Inspection city | Saint Paul |
| Inspection ZIP | 55130-2455 |
| Inspection start date | Mar 17, 2025 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: